Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club by Katarzyna Winter, Renata Talar-Wojnarowska, Andrzej Dąbrowski, Małgorzata Degowska, Marek Durlik, Anita Gąsiorowska, Stanisław Głuszek, Grażyna Jurkowska, Aleksandra Kaczka, Paweł Lampe, Tomasz Marek, Anna Nasierowska-Guttmejer, Ewa Nowakowska-Duława, Grażyna Rydzewska, Janusz Strzelczyk, Zbigniew Śledziński, Ewa Małecka-Panas

“…A vast majority of the statements are based on data obtained in clinical studies and experts’ recommendations on PDAC management, including the following guidelines: International Association of Pancreatology/European Pancreatic Club (IAP/EPC), American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), National Comprehensive Cancer Network (NCCN) and Polish Society of Gastroenterology (PSG) and The National Institute for Health and Care Excellence (NICE). …”
Get full text

Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer Treatment: Insights from the TOPAZ-1 Trial by Ralph Fritsch

“…This review summarizes the clinical evidence supporting the addition of durvalumab to CG in this indication, including the latest 3-year follow-up data from the TOPAZ-1 trial, presented at the Cholangiocarcinoma Foundation (CCF) 2024 Annual Conference and at the European Society for Medical Oncology Gastrointestinal Cancers (ESMO GI) Congress 2024, alongside real-world outcome data reflecting two years of clinical practice since FDA approval of durvalumab plus CG for first-line treatment of BTC. …”
Get full text

HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Canc... by Goran Bencina, Elina Petrova, Demet Sönmez, Sonia Matos Pereira, Ioannis Dimitriadis, Stina Salomonsson

“…To improve decision-making regarding the value of anticancer therapies and support standardized assessment for use by health technology assessment (HTA) agencies, the European Society for Medical Oncology (ESMO) has developed a Magnitude of Clinical Benefit Scale (MCBS). …”
Get full text

Awardee Summary of 2023 Taiwan Oncology Society Clinical Research Award Recipient: Persistent Endeavors on Research of Digestive Cancers for Three Decades by Kun-Huei Yeh

“…Third, on behalf of the Taiwan Oncology Society, we participated in and published the Pan-Asian adapted European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for locally advanced and metastatic CRC, gastric, and esophageal cancers, and the consensus meeting on tumor-agnostic indications of microsatellite instability-high (MSI-H) and NTRK. …”
Get full text

Adherence to guidelines for incidental pulmonary nodules: insights from a Nordic survey by Kirill Neumann, Janna Berg, Haseem Ashraf, Johan Isaksson, Aija Knuuttila, Morten H. Borg, Torben R. Rasmussen

“…Available international guidelines were equally represented, with 35% using the Fleischner Criteria, 30% using British Thoracic Society guidelines, and 35% using others (e.g. European Society for Medical Oncology, National Comprehensive Cancer Network). …”
Get full text

Comparative efficacy and safety of neoadjuvant radiotherapy for patients with borderline resectable, and locally advanced pancreatic ductal adenocarcinoma: a systematic review and... by Xin Wang, Dan Cao, Qingfeng Wang, Qiancheng Hu, Wanrui Lv

“…Electronic searching by titles using neoadjuvant treatments for PDAC will be performed in the annual meetings of European Society of Medical Oncology and American Society of Clinical Oncology (2018–2020). …”
Get full text

The impact of integrated genomic analysis on molecular classifications and prognostic risk stratification in endometrial cancer: a Chinese experience by Qian Zheng, Qian Zheng, Qian Zheng, Di Shao, Jin Shu, Jin Shu, Jin Shu, Qin Zhang, Qin Zhang, Qin Zhang, Min Huang, Dong Wang, Dong Wang, Dong Wang, Dongling Zou, Dongling Zou, Dongling Zou

“…With the application of the new European Society for Medical Oncology (ESMO) 2022 classification, 27 patients (14.1%) were reclassified. …”
Get full text

Clinical integration of germline findings from a tumor testing precision medicine program by Maria Carolina Sanabria-Salas, Nina C. Anggala, Brittany Gillies, Kirsten M. Farncombe, Renee Hofstedter, Larissa Peck, Helia Purnaghshband, Laura Redondo, Emily Thain, Wei Xu, Peter Sabatini, Philippe L. Bedard, Raymond H. Kim

“…Germline-focused analysis of TGVs followed the European Society of Medical Oncology guidelines and similar published criteria (‘tumor-only criteria’). …”
Get full text

Clinical Utility of Combined Tissue and Plasma Next-Generation Sequencing in Patients With Advanced, Treatment-Naïve NSCLC by Helena Bote-de Cabo, MD, Marco Siringo, MD, Esther Conde, MD, PhD, Susana Hernández, PhD, Fernando López-Ríos, MD, PhD, Alicia Castelo-Loureiro, MD, Esther García-Lorenzo, MD, Javier Baena, MD-PhD, Mercedes Herrera, MD, Ana Belén Enguita, MD, Yolanda Ruano, PhD, Jon Zugazagoitia, MD, PhD, Luis Paz-Ares, MD, PhD

“…Results: Forty-three patients in cohort 1 (34%) and 49 patients in cohort 2 (33%) harbored European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets (ESCAT) I or II targetable driver alterations. …”
Get full text